(0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Oct 25, 2021 10:00 AM - Oct 26, 2021 5:15 PM

(US Eastern Standard Time)

Real-World Evidence Conference

Translating Insights into Real-World Value.

Overview

Short Course: October 22
Conference: October 25-26

In a market that is constantly adapting and adjusting to the needs of the healthcare field, real-world evidence (RWE) is increasingly becoming important for regulatory and reimbursement decision-making. RWE, in relation to the real-world data that is collected in combination with the advancement of artificial intelligence-based analytics platforms, has led to the real-time analysis of data to better understand and gain insights on disease, approaches to treatment, and how to substantiate coverage decisions. Historically used for post-market safety monitoring, RWE is now becoming integrated throughout the product development lifecycle. DIA’s Real-World Evidence Conference will explore new and innovative applications of RWE and deliver cutting-edge insights through successful use cases, case examples, and practical applications on how stakeholders are leveraging RWE to advance healthcare knowledge and decision-making.



Featured

Want to learn more about Real-World Evidence Conference? You've come to the right site!

Continuing Education

Learn more

Exhibits

Learn more

Highlights & Features

Learn more

Who should attend?

Professionals involved in:

  • Real-World Evidence
  • Real-World Data
  • Epidemiology
  • Policy
  • Regulatory Science
  • Technology development
  • Data analytics
  • Clinical Research

Learning objectives

At the conclusion of this activity, participants should be able to:

  • Explain how RWE is being used today to inform biopharmaceutic development across product lifecycle
  • Discuss “lessons learned” from current uses of RWE by regulators, and how they can be applied for other future applications of RWE
  • Recognize general considerations and key features of successful RWE studies acceptable to the regulators for effective decision-making
  • Identify guidance and best practices for generating fit-for-purpose RWE for payers and HTA bodies
  • Define the expanding applications of RWE to support clinical trials and evidence generation
  • Evaluate the future applications of RWE in drug development
  • Appraise how mobile technologies, artificial intelligence, machine learning, and other technologies are being used to generate RWE
  • Evaluate how patient reported outcomes, electronic health records, and other patient data is expanding the resources for RWE

Short Course or Primer

To keep you at the forefront.

Oct 22, 2021

Short Course 1:

The Evolving Landscape of Real-World Data (RWD) and the Use of Pharmacoepidemiologic Methods and Machine Learning to Generate Credible Real-World Evidence (RWE)

Learn more

Program Committee

  • Paul Test Account Wong
    Paul Test Account Wong Associate Director, Meeting Op
    Drug Information Assoc, United States
  • Brian Bradbury, DrSc, MA
    Brian Bradbury, DrSc, MA Vice President, Center for Observational Research
    Amgen, United States
  • Dorothee Bartels, PhD, MSc
    Dorothee Bartels, PhD, MSc Chief Digital Officer
    Aetion, Germany
  • Paul M. Coplan, DrSc, MBA, MSc, FISPE
    Paul M. Coplan, DrSc, MBA, MSc, FISPE VP, Medical Device Epidemiology & Real-World Data Analytics
    Johnson & Johnson, United States
  • Simon Dagenais, PhD, MSc
    Simon Dagenais, PhD, MSc Real-World Evidence Lead, Internal Medicine
    Pfizer Inc, United States
  • Marni Hall, PhD, MPH
    Marni Hall, PhD, MPH VP & GM, Global Regulatory Science and Strategy
    IQVIA, United States
  • James Harnett, PharmD, MS
    James Harnett, PharmD, MS Executive Director, Health Economics and Outcomes Research
    Regeneron Pharmaceuticals, Inc. , United States
  • Jingyu (Julia) Luan, PhD
    Jingyu (Julia) Luan, PhD Senior Director, Global Regulatory Affairs, BioPharmaceuticals R&D
    AstraZeneca, United States
  • David Martin, MD, MPH
    David Martin, MD, MPH Vice President, Global Head RWE
    Moderna, United States
  • Delphine Saragoussi, MD, MSc
    Delphine Saragoussi, MD, MSc Executive Director, Real-World Evidence
    PPD, part of Thermo Fisher Scientific, France
  • Mark Stewart, PhD
    Mark Stewart, PhD Vice President, Science Policy
    Friends of Cancer Research, United States
  • Sulabha Ramchandran, PhD, MS
    Sulabha Ramchandran, PhD, MS Vice President and Head, US and Regions, Value Evidence and Outcomes
    GlaxoSmithKline, United States
  • Yun Lu, PhD, MS
    Yun Lu, PhD, MS Mathematical Statistician, Office of Biostatistics and Pharmacovigilance, CBER
    FDA, United States

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.